PROK
$2.13
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.
Recent News
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of -175.08% and -13.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -100.00% and -2.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Promising Penny Stocks With At Least $600M Market Cap
As U.S. stock indexes have started February on a high note, with the Dow Jones Industrial Average and S&P 500 showing impressive gains, investors are closely watching for opportunities in various market segments. Penny stocks, while often associated with smaller or less-established companies, remain relevant as potential investment areas due to their ability to offer value and growth opportunities that larger firms might miss. By focusing on penny stocks with strong financials and clear...
3 Penny Stocks With Market Caps Under $700M
Major U.S. stock indexes have recently pulled back after setting fresh all-time highs, reflecting a complex economic landscape influenced by geopolitical events and fluctuating oil prices. In this climate, investors often seek opportunities in lesser-known areas of the market where potential growth can be found. Penny stocks, despite their somewhat outdated name, represent such an opportunity by offering affordability and potential for growth when backed by strong financials.
ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright
ProKidney Corp. (NASDAQ:PROK) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” rating from slightly more than half of the analysts covering the stock. While the price target ranges from $1 to $12, the median price target of $6.50 reflects an upside […]